Patents by Inventor Salvatore J. Siciliano

Salvatore J. Siciliano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method and Apparatus for Automatically Isolating Microbial Species
    Publication number: 20080318310
    Abstract: This invention relates to an apparatus for streaking a sample on a media-coated (agar) plate in a predefined pattern utilizing a plate carousel system to house and retrieve a plate to a fixed location, a streaking mechanism having a floating stylus having a tip capable of gliding over the agar surface and depositing a sample onto the surface of the agar, a sample dispensing system and an optional wash station.
    Type: Application
    Filed: October 7, 2005
    Publication date: December 25, 2008
    Applicant: MERCK & CO., INC.
    Inventors: Claude Dufresne, Gary S. Kath, Gregory W. King, Prakash S. Masurekar, Salvatore J. Siciliano, Janet M. Sigmund, Neal R. Simpson, Stephen Skwish
  • Eosinophil eotaxin receptor
    Publication number: 20020192214
    Abstract: The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human &bgr;-chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.
    Type: Application
    Filed: August 6, 2001
    Publication date: December 19, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Bruce L. Daugherty, Julie A. Demartino, Salvatore J. Siciliano, Martin S. Springer
  • Eosinophil eotaxin receptor
    Patent number: 6271347
    Abstract: The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human &bgr;-chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.
    Type: Grant
    Filed: April 24, 1997
    Date of Patent: August 7, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Bruce L. Daugherty, Julie A. Demartino, Salvatore J. Siciliano, Martin S. Springer
  • Assay to identify human C5a antagonists and agonists
    Patent number: 5614370
    Abstract: The invention is an assay, including a series of peptides, which allow screening for inhibitors of C5a binding targeted to the subsite on the C5a receptor occupied by the C-terminus of C5a. These peptides allow compound testing efforts to be targeted to this same subsite so that C5a agonists and antagonists can be identified. These peptides have much greater affinity (Ki<10 nM) than does the natural C-terminus of C5a (Ki=300 .mu.M) and have been labeled to allow for detection of molecules which inhibit binding of these peptides at this receptor subsite. The invention is useful to develop agonists, partial agonists, and antagonists of C5a, and the invention includes compounds identified according to the method of this invention and methods of their use.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: March 25, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Zenon Konteatis, Salvatore J. Siciliano, Martin S. Springer